The current NICE guidance on B12 and folate deficiency sets this out clearly
The newer Egrifta WR formulation delivers 1.28 mg (0.16 mL) daily with the same efficacy but a smaller injection volume and easier preparation
Both drugs were developed at the University of Arizona
Before taking a GLP-1 drug, you should be aware that there are some potential risks associated with these medications, including: Allergic reactions Bowel obstruction Gallbladder problems, including bile duct blockages and gallstones Low blood sugar (hypoglycemia), especially when the GLP-1 is taken with insulin or oral diabetes medications Muscle loss due to rapid weight loss Nutritional deficiencies due to changes in food absorption Pancreatitis (inflammation of the pancreas) Slower absorption of oral medications, which may lead to reduced effectiveness of oral contraceptives and other drugs Thyroid tumors To help reduce the risk of some of these side effects, consider the following tips: Consume adequate protein and fiber Consume smaller, more frequent meals Limit alcohol intake Avoid high-fat foods Who should not take GLP-1 medication
Patients report a reduction in post-workout soreness duration, some initial visible changes in muscle fullness from improved glycogen storage, and the beginning of body fat reduction around the abdomen where GH-driven lipolysis preferentially acts on visceral fat stores
However they DO have some of the best formulations of Ipamorelin on the market
